Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.

Inclusion Criteria: * Life expectancy \> 10 years * Age ≥18 years. * World Health Organization (WHO) performance status 0-1. * Estimated life expectancy \>10 years. * Histological evidence of prostate cancer in the prostatectomy specimen * Primary tumor, regional nodes, metastasis (TNM): any primary tumor (pT), pathologically node-negative (pN0), M0. * Biochemical Recurrence (BCR) after prostatectomy, with 0.15 ≤ PSA \<0.70 ng/ml. * Patients must be able to comply with the protocol. * Signed informed consent. * Adequate laboratory findings (Haemoglobin (Hb) \>90g/L, absolute neutrophil count \>1.0x109/L, platelets \>75x109/l, bilirubin \<1.5x upper limit of normal (ULN), alanine aminotransferase (ALAT) \<5x ULN and creatinine \<1.5 ULN). Exclusion Criteria: * Metastases (regional lymph nodes or distant)\* diagnosed with imaging. * Prior or ongoing hormonal therapy (antiandrogens or gonadotropin releasing hormone). * Prior radiotherapy to the pelvis. * Prior malignancy other than prostate cancer and basalioma in the past five years. * Clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) class III-IV congestive heart failure. * Severe pulmonary disease. * Any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial.